FT Digital Health Summit Europe

FT Live Calendar

10/06/2015

8:00 am	Registration & networking
9:00 am	Chair’s opening remarks
9:10 am	Leaders Forum: The role of digital health in the wider pharmaceutical, life science and healthcare arena It is a crucial time for the digital health community with 2015 being what many are predicting as the ‘industry take-off’ year. Whilst impressive innovation continues to arrive and receive public acceptance, companies are concerned with how national public healthcare systems, regulations and professionals, will be able to successfully incorporate this technology into everyday health and wellness. In order for an effective transition period to take place, the industry must first address the likely challenges to occur. The opening panel of leading stakeholder voices from Europe’s healthcare, life sciences, pharmaceuticals and technology providers will share their various perspectives on this inevitable transition. Where will continued drive in digital health come from? Consumers or the industry? How will new technologies change the way healthcare data is used and managed? The role of ‘big data’ in healthcare delivery Mapping the macro-business trends impacting the digital health ecosystem Sir John Chisholm, Chief Executive Chair, Genomics England Jessica Federer, Chief Digital Officer, Bayer Will Cavendish, Director General – Innovation, Growth and Technology, UK Department of Health
10:00 am	CMO panel: Incorporating digital innovations into mainstream public healthcare Many would argue that the entire healthcare industry is at a crossroads right now. As healthcare becomes more unaffordable and technology continues to capture public imagination, new healthcare delivery models are starting to become available. The whole future delivery system for healthcare is undergoing change and this is due to technology and digital data, but how will public and private healthcare systems react? This panel, featuring industry-leading Chief Medical Officers, will determine the future impact of data and technology when it comes to everyday health care practices. Are healthcare systems now moving closer to the patient? How long will the traditional face-to-face doctor-patient relationship last? What’s the likely timeline until patients have dominant control of their own care and their own medical data? How will medical professionals keep up with constantly changing technological trends? What opportunities are there for partnerships within healthcare delivery? Dame Sally Davies, Chief Medical Officer, England Murray Stewart, Chief Medical Officer, GlaxoSmithKline Klaus Dugi, Senior Vice President Medicine and Chief Medical Officer, Boehringer Ingelheim Paul Zollinger-Read, Chief Medical Officer, Bupa
10:50 am	Morning refreshments
11:20 am	Keynote interview
11:40 am	Investment panel: Bridging the gap between venture capital, private equity and investment banking in digital health As larger corporations move into the sector and digital data continues to gather pace, it is highly likely that the digital health industry will now start to scale up. Will companies finally be able to crack this market and accelerate growth? If they are then investors will need to play a key role in order to make sure that this growth is scalable and commercial. There has been much start-up innovation in this sector, primarily through venture capitalists that have played significant roles in helping digital health technologies catch the consumer eye but what would the impact be when private equity and investment bankers join the game? Now that leading technology corporations are moving into the digital health space, what interest do investment bankers now have? How do investors now view the bottom line in light of digital health uptake? What are the main threats from reimbursement risk? Which stakeholder sector are investors eyeing up and why? Philipp Gutzwiller, Head of Healthcare, Lloyds Banking Group
12:20 pm	Panel: The adoption of digital health practices – who will pay for healthcare delivery? Digital health will require new payment and business models based on reimbursement in accordance with the value they bring to healthcare services. In some cases, the business model and reimbursement will be based upon finding ways of effectively driving down costs in the healthcare system, often working in collaboration with multiple stockholders. Yet incentives across the system of healthcare are most often misaligned. What are the latest emerging business models? How can incentives be better aligned? Identifying examples of organisations that have been successful in gaining reimbursement for digital health enabled services What are payers looking for in their decision making with regards to reimbursement of digital services?
1:00 pm	Networking lunch
2:00 pm	Regulation panel: Avoiding the regulatory pitfalls when it comes to digital transformation Digital health will inevitably bring with it a whole host of regulatory implications. Forecasting what these implications will be when healthcare migrates onto consumer digital devices will be critical for the effective transition of healthcare services. For example a smart phone can monitor a large range of health conditions but if, due to digital transformation, it turns into a medical device, is it not therefore subject to regulation? Will regulation stifle digital health as has been seen in some other digitalised industries? How will regulation allow for clarity and growth when it comes to defining what is a medical device and what is a health application? Can we avoid regulation stumbling in the way of digital health innovation? How can governments and health services encourage the effective uptake of digital transformation into the health industry? Pēteris Zilgalvis, Head of Unit eHealth and Well Being, DG CONNECT European Commission
2:50 pm	Innovation panel: Assessing new technologies in healthcare, pharmaceuticals and biotechnology From smart pills to 3D bioprinting, to digestible and wearable sensors to nanorobotics and next generation gene sequencing and beyond, the vast array of technologies under development has the potential to completely transform health and medicine. What are the technologies under development? Which have the greatest potential for transformation into healthcare services? Which will make their way into clinical practice? Can they provide evidence in terms of their usability and their ability to reduce costs in healthcare systems? Tony Young, National Clinical Director for Innovation, NHS England Ger Brophy, Chief Technology Officer, GE Healthcare Life Sciences
3:40 pm	Afternoon networking break
4:00 pm	Panel: The role of emerging markets in the development of connected digital health services Much has been written about the promise of mobile and digital health in developing countries. The recent Ebola outbreak where digital applications are being used to help track the spread of the disease provides examples of what can achieved in the public health arena. The potential impact that digital health could have on emerging markets is substantial as much of the healthcare needs to be delivered to highly remote areas where healthcare premises do not exist. This in turn calls for a drive in more remote and mobile technologies. What have been the successes when it comes to digital health systems in emerging markets? What needs to be done to drive digital health efficacy and efficiency forward?
4:40 pm	Keynote interview: Learning from lessons in digital transformation to ensure healthcare is stable and manageable The health sector has been slow compared to other industries in embracing the digital opportunity. Featuring an in-depth Q&A session between an FT journalist and a CEO of a retail, banking or travel organisation, what can the health industry learn in terms of expected barriers and how to overcome them?
5:00 pm	Chair’s closing remarks
5:15 pm	Networking drinks reception